The Company accepts ESR submissions via our submission tool. The AstraZeneca Research Grant seeks medical research proposals from researchers affiliated to accredited Nigerian medical schools and research institutions who show promise of delivering medical research of high scientific merit. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Deadline: October 12, 2020. Bioz Stars score: 90/100, based on 1 PubMed citations. Research proposals and protocols are reviewed on a regular basis by Company Review & Evaluation Groups, which include members from Medical, Biostatistics, and Regulatory functions. Over $900,000 in Research Grants Focused on Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) and Immunotherapies . Fellows Research Establishment Fellowship . Find more information about AstraZeneca’s Access 360 and other support programs that are available for healthcare professionals, and learn more about AstraZeneca research and development. Resistance profiling - alternative combination studies where MET+ is a resistance mechanism. infectious vs. non-infectious), ICS-containing therapy in early (vs. mild or severe) COPD, in order to prevent disease progression, Role of PDE4 inhibition in COPD-related inflammation, The risk of muscular skeletal syndrome (MSS; joint fibrodysplasia), while reversible, has been seen after chronic administration with other MPP inhibitors in humans and fibrodyplasia in the subcutis has been seen at high doses in the 12 month preclinical safety study with AZD1236. Please note, approval of a proposal does not imply or guarantee approval of a protocol. All contributions made by AstraZeneca are paid only directly to US-based nonprofit organizations. We are not currently seeking proposals in oncology indications. Proposals for non-oncological indications may be of interest. Access to this tool, information on the available products/compounds, and the associated areas of interest for ESR can be found on this page. Article Snippet: Shaun Goodman received research grant support and speaker/consulting honoraria from 10.13039/100004325 AstraZeneca , 10.13039/100004326 Bayer , 10.13039/100008021 Bristol Myers Squibb , 10.13039/501100002973 Daiichi-Sankyo , Eli 10.13039/100004312 Lilly , 10.13039/100004334 Merck, and 10.13039/100004339 Sanofi . PUBLISHED 5 February 2019. StepUp!, part of AstraZeneca’s Young Health global grants programme, aims to extend the reach and impact of AstraZeneca’s investment in young people’s health. Non-Clinical Research (pre-clinical research) – in vitro, in vivo or ex vivo biomedical research not performed on human subjects such as: pharmacodynamic, pharmacokinetic, animal, microbiologic, human biological samples (biomarker, diagnostic assay): Oncology – requests for non-clinical research involving compounds across all phases of development can be made via the AstraZeneca, Non-Oncology Therapy Areas – requests for non-clinical research involving compounds in phase III development or beyond can be made via, Research proposals are evaluated strictly on their scientific merit and alignment with the Company´s overall research and global development strategy, As required by law, we disclose financial support provided to researchers and their institutions, Funding of research must not exceed local fair market value, nor be used for expenses not associated with the conduct of the research, Submit a well-written proposal supported by pre-clinical or clinical data with strong scientific rationale, Have the scientific, technical and operational capabilities to conduct the study, Be able to submit an Investigational New Drug Application (IND)/Clinical Trial Application (CTA), if necessary, Provide contractual agreed-upon study status updates, Have expert statistical support available for data analysis, Preclinical reprotoxicology data are available and have not identified any specific risks. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Opportunities for development in Breast cancer: Combinations studies with targeted biological agents: Accepting Externally Sponsored Clinical Research Proposals  for drug only in allogenic stem cell transplantation, EGFR sensitising and T790M Resistance Mutations Inhibitor, Accepting limited number of Externally Sponsored Clinical Research Proposals. This brings to 18 the total number of research grants conferred locally by the Trust since its inception. Early use in PN patients prior to emergence of severe symptoms and need for surgery, Studies exploring re-treatment with selumetinib in patients who have come off therapy (for reasons other than toxicity or progression) for >3 months, Adjuvant/Neo adjuvant use in combination with debulking surgery, Country-specific real world evidence studies, Studies exploring combinations to deepen the response in adult patients, Country-specific studies real world evidence studies, Pathway related paediatric tumours Seroquel CAF and AstraZeneca will act as controllers in common for the purposes of your data. However, applicants are expected to accept the first grant they are awarded. Veeva ID: Z4-25396Date of next review: August 2022. 5m in Grants Being Allocated to Academic Medical Research Monday, 19 January, 2015 The AstraZeneca Research Trust, a non-profitable Trust for the disbursement of academic medical research funding is calling for 2015 research proposals. The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, is a COVID-19 vaccine developed by Oxford University and AstraZeneca given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1. ASTRO funds research in radiation biology, cancer biology and radiation physics for junior faculty, residents, fellows and postdoctoral fellows. Proposals should be supported by a strong scientific rationale, preclinical data package and specific hypotheses to address. Women of child-bearing potential using highly effective contraception can be included, Proposed indications should be evaluated against the risk of hypoglycaemia in non-diabetic subjects, Preclinical reprotoxicology data is not available for this compound. Grant Reporting National Physician Payment Transparency (OPEN PAYMENTS) OPEN PAYMENTS (Federal Sunshine Act) is the name of the CMS website where information for applicable manufacturers, physicians and teaching hospitals is posted, and where the payment and transfers of value data will be available for public access. Understand impact of COVID-19 overall burden on communities, spectrum of disease in communities, and level of herd immunity. Proposals for ESR will not be endorsed, unless if a major data gap has been identified, Accepting proposals in Japan and China only. Durvalumab +/- tremelimumab in NSCLC patients excluded from the registration program (un-resectable Stage IIIA / IIIB and Stage IV), Durvalumab-based combinations in immunotherapy pre-treated patients, Durvalumab +/- tremelimumab combinations with chemotherapy, radiotherapy or other agents (immunotherapy / targeted therapies), Enhance biomarker knowledge to support clinical decision making for durvalumab-based combinations, Early predictors of clinical activity and immune-related adverse events, Patient reported outcomes and patient experience of patients receiving durvalumab +/- tremelimumab in NSCLC, Durvalumab +/- tremelimumab combined with SoC chemotherapy in front-line metastatic urothelial cancer, Durvalumab +/- tremelimumab combined with novel agents or radiotherapy in front-line or relapsed bladder cancer, Optimal utilization of Durvalumab +/- tremelimumab in non-muscle invasive bladder cancer, Durvalumab +/- tremelimumab combined with SoC chemotherapy, novel agents, or radiotherapy in patients with stage II– IV non-metastatic disease, Real-world evidence (RWE) on treatment patterns and outcomes with introduction of checkpoint inhibitors in bladder cancer, Prognostic value of PD-L1 expression in patients with bladder cancer treated with the SOC, Patient reported outcomes and patient experience of patients receiving durvalumab +/- tremelimumab in bladder cancer, Durvalumab +/- tremelimumab in HNSCC patients excluded from the registration programs, Durvalumab +/- tremelimumab in locally advanced HNSCC sub-populations, Durvalumab +/- tremelimumab combined with targeted agents (e.g. ET. For enquiries relating to availability, ordering or delivery of our medicines - please call our Supply Chain Team on 0800 0320501. If you apply for this grant programme, you will be directed to CAF’s carefully selected service provider (Blackbaud) to enter the details of your application. ASTRO funds research in radiation biology, cancer biology and radiation physics for junior faculty, residents, fellows and postdoctoral fellows. The inclusion of women of child-bearing potential using highly effective contraception in trials of modest size and duration could be considered based on the risk benefit and in accordance with territory specific requirements, Preclinical safety studies support future clinical studies of up to 3 months duration with the need for monitoring liver enzymes, thyroid, and adrenal function. New insights into the mode of action, potential pleiotropic effects, biochemical pathways and clinical effects of SGLT-2 inhibition with dapagliflozin focusing on vascular function, heart failure, cardiovascular risks. Email: Medical.InformationUK@astrazeneca.com . Proposals for non-oncological indications may be of interest. Special Initiatives and/or Representative Health and Human Services Grants:Connections for Cardiovascular Health SM (CCH)—The AstraZeneca HealthCare Foundation awarded CCH grants to 11 nonprofit organizations in 2018 working to help prevent and/or manage cardiovascular disease by conducting programs for at-risk groups and tailoring activities and information to the needs and … Studies in patients with eosinophilic asthma to: Investigate and identify predictors of enhanced response to benralizumab, Understand the overlap between different T2 biomarkers and the effects of benralizumab, Investigate early onset of patient-centric and clinical benefits of benralizumab. The inclusion of women of child-bearing potential would need to be assessed for any proposal based on the risk benefit and the use of appropriate highly effective contraception. In response to this unmet need, the AstraZeneca Research Trust has awarded another seven local grants totalling R1.5m for the 2015/2016 year. AstraZeneca has received more than $1 billion from the U.S. Health Department's Biomedical Advanced Research and Development Authority to develop a coronavirus vaccine from the University of Oxford. You are about to access AstraZeneca historic archive material. Once a clinical ESR proposal is reviewed and approved, the non-Company researcher will be invited to submit a full protocol for review. AstraZeneca strongly believes that interactions with Health Care Providers (HCPs) and Healthcare Organisations (HCOs) positively influence the quality of patient treatment and the value of medical research. Such grants are made according to AstraZeneca policy and procedure for projects benefitting patient care and/or medical research. AstraZeneca in the UK A global pharmaceutical company with a major UK presence. The first peer-reviewed paper proclaiming the alleged efficacy and safety of the Oxford-AstraZeneca COVID-19 vaccine (also known as the "ChAdOx1 nCoV-19 vaccine" or "AZD1222") was published online in the Lancet on 8 December 2020. This research is the first to examine how a COVID vaccine works on transmission, alongside confirming that the UK approach to administering doses (12 weeks in between as opposed to 3 or 4) is supported by the outcome. The Grant seeks to enhance health research capacity in Nigeria by supporting local research that will advance knowledge and improve practice in various specialties The AstraZeneca Step Up!Global Grants Programme is now open for applications for health promotion programmes running from 2021 to 2022. We encourage you to read the privacy policy of every website you visit. Mechanistic studies in relevant disease-state models to: Study the effect of eosinophil depletion by benralizumab on airway structure/function and cellular/molecular pathology, Characterise the role and effect of benralizumab on other IL-5R expressing cells beyond eosinophils, Real world studies in eosinophil-driven diseases other than asthma that provide information about patient characteristics and disease burden, Mechanistic or clinical studies in eosinophil-driven diseases other than asthma that are not addressed by currently sponsored development programmes, Studies related to exacerbations and/or suitable patient populations, Impact of first and subsequent exacerbations, Clinical and economic impact of non-severe exacerbations, Identification of patients that are at risk of exacerbation, Evidence supporting the role of triple therapy in symptom improvement, Identification of patients  likely to respond to ICS, Studies related to the clinical/economic benefit of ICS as part of triple therapy, Relationship between safety/tolerability and patient benefit of FDC triple therapy, Clinical/Economic impact of ICS use as an early treatment for COPD, The benefit of pMDI device in patients with COPD, Novel technologies to measure clinical response, including imaging and mechanistic studies, Evidence informing the value proposition of connected device technology, Correlations between SABA use, ICS use and patterns of asthma exacerbations, Mechanisms linking the variability of inflammation, symptoms and exacerbations, Long-term health consequences of intermittent OCS bursts. To help address the most profound of these challenges, the LCRF-AstraZeneca grant program aims to fund innovative projects to: Understand primary and acquired resistance to osimertinib and novel combinations targeting concurrent driver mutations Proposals will be prioritized accordingly based on scientific merit and fit with the clinical program. That research, which is yet to be peer reviewed, examined the effectiveness of the first dose of the Pfizer and AstraZeneca vaccines in a national study of about 5.4 million people. Other AstraZeneca sites: Select your country from our list of global sites … The World Health Organization announced Monday it has approved two versions of the AstraZeneca-Oxford COVID-19 vaccine for emergency use, a … AstraZeneca is committed to supporting and enabling quality independent medical and scientific education as well as charitable support that will enhance patient care and meets our standards of quality and compliance. Proposals with a supporting translational / exploratory mechanistic research package to understand the role and interplay of MET and the immune-microenvironment will be prioritised. The Lung Cancer Research Foundation (LCRF) today announced a collaboration with AstraZeneca to fund over $900,000 in research grants focused on … AstraZeneca is committed to the same ethical policy that is practiced during grant and manuscript peer-reviews. Life at AstraZeneca. Accepting the following clinical Externally Sponsored Research Proposals: Monoclonal antibody to the type I IFN receptor subunit 1, budesonide / glycopyrronium / formoterol FDC in COPD, Inhaled steroid/long acting Beta2 agonist, Matrix metalloproteinase 9 & 12 (MMP9,12) inhibitor, We are currently not accepting any ESRs related to Long Acting Antibodies research (LAAB). How and when are decisions made? AstraZeneca provides a single way to facilitate and manage external funding requests such as medical education grants, sponsorships, contributions, fellowships and corporate memberships. All contributions by AstraZeneca are a one-time commitment without guarantee of renewal unless otherwise agreed by both parties in a Letter of Agreement. The AACR-AstraZeneca Stimulating Therapeutic Advances through Research Training (START) Grants represent an exciting new initiative to encourage and support such collaboration. EMA has recommended granting a conditional marketing authorisation for COVID-19 Vaccine AstraZeneca to prevent coronavirus disease 2019 (COVID-19) in people from 18 years of age. Community Investment funding includes financial and non-financial (in-kind) support given to registered charity and non-profit organisations for health and health initiatives, science education, fundraisers and disaster relief. What we do . These are individuals who showed promise of delivering medical research of high scientific merit. Applications for the 2021 Fellowship are no longer being accepted. AstraZeneca Research Grant awarded four exceptional researchers with grants to the tune of over sixteen million naira. Your data will only be used for the purposes of this programme. Please utilize our Global RAPID Pre-assessment to determine what application process to follow based on the nature of your proposal. Investigate the potential role of TSLP in different asthma endotypes and phenotypes i.e. Examples:Membership at the AZ level (not individual level), Trade Associations. Women of child-bearing potential using highly effective contraception can be included. (Source: Journal of Clinical Lipidology) Source: Journal of Clinical Lipidology - June 30, 2020 Category: Lipidology Authors: G.B. Real-world clinical and economical benefits of budesonide/ formoterol as a reliever across all asthma severities. New insights into the mode of action, potential pleiotropic effects, biochemical pathways and clinical effects of SGLT-2 inhibition with dapagliflozin focusing on kidney pathophysiology. cetuximab, AZ targeted small molecules etc. Our contribution to the UK. Grant requests of this type should not be made through the AstraZeneca HealthCare Foundation’s Connections for Cardiovascular Health℠ program. PLEASE NOTE THAT ASTRAZENECA IS UNABLE TO REVIEW PROPOSALS FOR STUDIES INVOLVING PEMBROLIZUMAB AND LYNPARZA. SCLC, GI tumours) supported by robust preclinical data may be considered, Priority will be given to proposals that advance understanding of core development programs in NSCLC, Bladder and HNSCC, Pre-clinical studies will be considered through the AstraZeneca, Studies that overlap or compete with AstraZeneca development program or where there is compromised or excessive safety risk will not be accepted, Non-oncology indications will not be supported at this time, First-line for patients with advanced breast cancer after adjuvant AI, Adding novel targeted agents after progression on Faslodex, Peri- and pre-menopausal women as monotherapy or in combination (e.g. AstraZeneca research grants nih scientific advisory board afsp Research Grants Nih Scientific Advisory Board Afsp, supplied by AstraZeneca, used in various techniques. AstraZeneca is also committed to supporting high quality independent continuing medical education that enhances patient care and meets our standards of quality and compliance. What is the submission review process? Oral VEGF receptor -1-2-3 kinase inhibitor, Immuno-modulator; a human mAb of the immunoglobulin G1 kappa (IgG1κ) subclass that inhibits binding of Programmed Death Ligand 1 (PD-L1) to PD-1 and CD80, Selective Estrogen Receptor Downregulator. Real World Evidence: local data generation to describe anaemia and its management, CKD. For all Medical Information enquiries, about the AstraZeneca COVID-19 vaccine and to view the Information for UK Vaccine Recipients and Information for Healthcare Professionals please click here.. 11-beta-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) inhibitor, Exploring the Effects of Dapagliflozin on the Cardiovascular System, Exploring the Effects of Dapagliflozin on the Renal System, Other research focus areas will be considered so as not to restrict scientific creativity, Accepting proposals in China only (previous confirmation with Xi Zang Kang Zhe Pharmaceutical development Co., Ltd.), Renal disease (no substance or brand involved), Oral, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). IF YOUR IDEA INVOLVES THE USE OF PEMROLIZUMAB, THEN PLEASE SUBMIT YOUR APPLICATION TO MERCK, WHO ARE RESPONSIBLE FOR THIS COMBINATION. Supply chain. Not accepting non-clinical Externally Sponsored Research Proposals at this time Tuesday, 4 February 2014. Tenable: Australia, Aotearoa New Zealand or overseas. Not accepting Externally Sponsored Clinical Research Proposals. Requestors of medical education or research grants should visit the AstraZeneca Request Support webpage for more information on opportunities available through AstraZeneca Pharmaceuticals. eosinophils, IgE, FeNO etc. optimal duration of therapy), Optimization of 1L testing to improve turnaround times, Identify new testing approaches to improve the quality and speed of treatment decisions in metastatic and early disease, Understand the prevalence and impact of other biomarkers e.g. Accepting limited Externally Sponsored Clinical Research Proposals in combination with durvalumab in H&N”. Research Grant on Disparities RFP. As an organisation centred around what makes us human, we put a big focus on people. AstraZeneca provides this link as a service to website visitors. Proposals for Oncology indications using tremelimumab alone or in combination with other products (with the exception of durvalumab-based combinations - see the durvalumab areas of interest for further information), are not sought at this time. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Designation based on positive primary analysis of the Phase IIb trial that demonstrated the safety and efficacy of MEDI8897 . Grants & Sponsorships We will be prioritising drug-only requests. with GNRH agonists, novel targeted agents), Patients with different molecular pheonotypes (e.g Luminal B breast cancer). Requestors of medical education or research grants should visit the AstraZeneca Request Support webpage for more information on opportunities available through AstraZeneca Pharmaceuticals. Proposals for Oncology indications are not sought at this time. Value: Up to AUD$75,000 for 1 year. Deadline: October 12, 2020. No. The ASTRO-AstraZeneca Radiation Oncology Research Training Fellowship is a joint effort to provide physician-scientists with real-world experience in late-stage clinical trial development at the facilities of AstraZeneca and its Affiliates. in non-CRT eligible EGFRm patients), Explore ctDNA and other biomarkers to help guide treatment decisions in the early disease setting (E.g. Proposals shall be prioritized accordingly based on scientific merit and fit with the core development program. AstraZeneca Research Grant 2002 ～ バーチャル研究所構想に向けて着実に前進 ～ PUBLISHED 2002年 9月 10日. No. Eligibility: Australian and Aotearoa New Zealand Fellows and Advanced Trainees of the RACP's Divisions, Faculties and Chapters. Rapid identification of 1L resistance mechanisms using tissue, to accelerate new combination options, Benefit/risk of treatment beyond progression, Understand biomarkers of poor initial response to 1L TAGRISSO, Extend survival benefit using TAGRISSO in combination with  targeted and non-targeted approach’s, Establish evidence to support appropriate position of IO agents in EGFRm patients (advanced and early disease), Generate RWE data on 1L TAGRISSO including patient preference, Develop insights into the 1L treatment journey to reinforce the benefits of starting with the best EGFR TKI first, Assess the risk of CNS disease progression with 1, Develop treatment insights into the early disease setting, including EGFR prevalence through early screening, Build prospective evidence for CNS risk reduction, Build efficacy in leptomeningeal metastases, and symptomatic CNS patients using the 80mg dose, Use of TAGRISSO in combination with Stereotactic radiotherapy, and in combinations with other systemic agents, Translational assessment of tumour micro-environment post-surgery in the neoadjuvant setting, Address optimal treatment strategy for downstaging tumors (e.g. The AstraZeneca HealthCare Foundation’s Connections for Cardiovascular Health SM program today announced a grant of $238,900 to the Sundance Research Institute to support its Honoring Your Heart on the Wind River Indian Reservation initiative.. Applicants must plan to spend one year on site at an AstraZeneca facility. In 2016, the Gates Foundation gave $36 million to a team of researchers that was headed by … No contributions are made to individuals or for-profit organizations. AstraZeneca UK aims to support local innovation and best practice that improves patient care in Respiratory, Immunology, Cardiovascular, Metabolic, Renal and Oncology therapy areas. In particular, concepts that address an important scientific question and could be relevant across a range of B-cell diseases, Evaluation of surrogate marker endpoints predictive of long-term outcomes with acalabrutinib treatment, Data generation specific to regional needs where the standard of care may differ, Evaluation of treatment duration, including the addition of other therapeutic agents to assess the clinical benefit of continuing acalabrutinib beyond initial progression, Assessments of real world data, including comparison with other novel agents, Studies evaluating the role of maintenance therapy with acalabrutinib. Oncology Externally Sponsored Research Handbook – guidance on how to work successfully with AstraZeneca and advice on key challenges encountered during ESR. triggers), Investigate mechanism of action of tezepelumab in asthma and effects on airway/structure function and cellular/molecular pathology, Biomarkers of response to inhaled corticosteroid-containing therapies in COPD, Biomarkers to characterize COPD pheno and/or endotypes that benefit from non-ICS-containing therapies, Understand inflammation in COPD vs. non-inflammatory features of the disease (e.g. Accepting limited Externally Sponsored Clinical Research Proposals. provides grants of up to US$10,000 to help small, innovative, youth-focused non-profits develop and deliver effective health promotion programmes – with an emphasis on under-resourced and marginalised … AstraZeneca is committed to support medical & scientific education through sponsorships, fellowships and collaborations to enhance contribution to the patients all over the world. The Grant seeks to enhance health research capacity in Nigeria by supporting local research that will advance knowledge and improve practice in various specialties Externally Sponsored Scientific Research (ESR) is research that is initiated and managed by a Non-Company Researcher who assumes the legal and regulatory responsibility for the conduct and management of the research as defined by applicable regulations and laws of the country involved. The World Health Organization announced Monday it has approved two versions of the AstraZeneca-Oxford COVID-19 vaccine for emergency use, a … We’re curious about science and the advancement of knowledge. 2020 has been a difficult year for all, but has seen 58 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) be developed and in clinical trials,1 with some vaccines reportedly having more than 90% efficacy against COVID-19 in clinical trials. Step Up! 1 Lungenclinic, Airway Research Center North, German Center for Lung Research, 22927 - Grosshansdorf/DE; 2 Department Of Clinical Oncology, Chinese University of Hong Kong, Hong Kong/CN; 3 Thoracic Oncology Program, AdventHealth Cancer Institute, 32803 - Orlando/US; 4 Department Of Medical Oncology, Rocky Mountain Cancer Centers, Denver, Co, United States Of America, Department … One dosing regimen showed 90% efficacy when a half-dose was followed by a full-dose after at least one month, based on mixed trials with no participants over 55 … GBJM received research grant(s)/support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novo Nordisk, and Sanofi, and has served as a consultant for these companies as well as Esperion, Novartis, and Servier. Grants and Donations may be awarded to Healthcare Organisations, Patient Organisations, or … Observational research into routine clinical management of patients with chronic kidney disease. Given the potential effects on liver enzymes, dosing regimen (level and duration) as well as inclusion/exclusion criteria should be selected carefully to support a favourable risk-benefit. Decisions are typically communicated within 45 days of receipt of a complete submission. Humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody (mAb) that specifically binds to and triggers signaling of human OX40, Accepting limited Externally Sponsored Clinical Research Proposals, c-Met receptor tyrosine kinase inhibitor (TKI). Limited to combinations outside of ongoing internal program with strong scientific rationale, HER2-targeting Antibody Drug Conjugate (ADC). Areas of interest will be: Other research focus areas will be considered as to not restrict scientific creativity, Gamma-aminobutyric Employment. XR (quetiapine As well as joint working with the NHS, AstraZeneca also provides occasional grants to the NHS, affiliated research institutions and other Healthcare Organisations (HCOs). Launched last year, the Trust will again award R1.5 million to local academic research - … Please refer to your approved national product label (SmPC) for current product information. It includes donations of medicines in response to public health needs related to national and international disasters and humanitarian crises or as part of free goods Patient Assistance Programmes. AstraZeneca Australia is part of the global science-led biopharmaceutical company, AstraZeneca. We follow a strict code of ethics which ensures we are compliant with regulations and ethical standards.